News · 26 weeks35-67%
2025-10-262026-04-19
Mix2590d
- Insider11(44%)
- Other6(24%)
- Earnings4(16%)
- SEC Filings3(12%)
- Analyst1(4%)
Latest news
25 items- PRMIMEDX to Host First Quarter 2026 Operating and Financial Results Conference Call on April 29MARIETTA, Ga., April 22, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the first quarter ended March 31, 2026 after the market close on Wednesday, April 29, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13759618 A replay of the webcast will be available for approximately 30 days on the Company's
- SECMiMedx Group Inc filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
- PRMIMEDX Announces Restructuring and Cost Reduction InitiativeMARIETTA, Ga., April 16, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced a series of cost reduction initiatives intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses. As part of these changes, the position of Chief Operating Officer, held by Ricci Whitlow, has been eliminated. "On behalf of the Board and management team, I want to thank Ricci for her innumerable contributions to MIMEDX and her exceptional leadership in helping to build and scale our operations," stated Joseph H. Capper, MIMEDX Chief Executive Officer. "Ricci joined the Company at a pivotal time in the organizatio
- PRMIMEDX to Sponsor Leading Advanced Wound Care ConferencesMultispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced its participation in two leading wound care conferences: the Symposium on Advanced Wound Care ("SAWC") Spring 2026 and MedStar Georgetown University Hospital's Diabetic Limb Salvage ("DLS") Conference. Through scientific presentations, clinician education, and exhibit presence, MIMEDX will highlight its growing body of clinical evidence and expanding portfolio of solutions designed to support clinicians in m
- PRMIMEDX Announces Launch of CHORIOFIX™MARIETTA, Ga., March 23, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the commercial launch of CHORIOFIX™, the latest advanced wound care innovation in its product portfolio of placental allografts. "CHORIOFIX is an organically developed product, created based on our deep understanding of the scientific and clinical attributes of the chorion layer," stated Michelle Massee, MIMEDX VP, Research & Development. "It consists of two chorion layers with an intact intermediate layer, making it our thickest product to date. The allograft's structure enhances handling, particularly during positioning and suturing, while its uniform, dual-side
- INSIDERGeneral Counsel and CAO Hulse William Frank Iv covered exercise/tax liability with 20,245 shares, decreasing direct ownership by 4% to 543,195 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Commercial Officer Maersk-Moller Kimberly covered exercise/tax liability with 6,762 shares, decreasing direct ownership by 2% to 329,450 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Commercial Officer Maersk-Moller Kimberly exercised 42,845 shares at a strike of $4.50 and covered exercise/tax liability with 21,270 shares, increasing direct ownership by 7% to 336,212 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERGeneral Counsel and CAO Hulse William Frank Iv covered exercise/tax liability with 61,460 shares and exercised 136,364 shares at a strike of $4.50, increasing direct ownership by 15% to 563,440 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Financial Officer Doug Rice exercised 243,000 shares at a strike of $4.50 and covered exercise/tax liability with 96,363 shares, increasing direct ownership by 55% to 412,315 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Executive Officer Capper Joseph H was granted 371,094 shares, increasing direct ownership by 70% to 904,656 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Financial Officer Doug Rice was granted 74,163 shares, increasing direct ownership by 39% to 265,678 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERGeneral Counsel and CAO Hulse William Frank Iv was granted 74,987 shares, increasing direct ownership by 18% to 488,536 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Operating Officer Whitlow Ricci S was granted 74,163 shares, increasing direct ownership by 19% to 462,825 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- INSIDERChief Commercial Officer Maersk-Moller Kimberly was granted 74,163 shares, increasing direct ownership by 31% to 314,637 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- PRMIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid ShieldsMARIETTA, Ga., March 05, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the commercial launch of AMNIOFIX Thyroid Shields, a product line extension of the Company's AMNIOFIX dehydrated human amnion/chorion membrane (DHACM) allografts. AMNIOFIX Thyroid Shields are allografts designed and intended for use in endocrine surgery. Following a thyroidectomy, the sheets—provided in preconfigured sizes—are applied to the exposed Recurrent Laryngeal Nerve (RLN) and parathyroid glands to provide a protective barrier and thereby support the healing cascade. The product is designed to prevent the need for intraoperative modification, saving valu
- PRMIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial ResultsNet Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of $340-360 Million Announces $100 Million Share Repurchase Program Authorization Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the fourth quarter and full year 2025. Joseph H. Capper, MIMEDX Chief Executive
- SECMiMedx Group Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MIMEDX GROUP, INC. (0001376339) (Filer)
- SECSEC Form 10-K filed by MiMedx Group Inc10-K - MIMEDX GROUP, INC. (0001376339) (Filer)
- ANALYSTCitizens initiated coverage on MiMedx Group with a new price targetCitizens initiated coverage of MiMedx Group with a rating of Mkt Outperform and set a new price target of $10.00
- INSIDERChief Operating Officer Whitlow Ricci S covered exercise/tax liability with 61,961 shares, decreasing direct ownership by 14% to 388,662 units (SEC Form 4)4 - MIMEDX GROUP, INC. (0001376339) (Issuer)
- PRMIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25MARIETTA, Ga., Feb. 17, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, February 25, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-6184International Investors: 201-389-0877Conference ID: 13758446 A replay of the webcast will be available for approximately 30 days on
- SECAmendment: SEC Form SCHEDULE 13G/A filed by MiMedx Group IncSCHEDULE 13G/A - MIMEDX GROUP, INC. (0001376339) (Subject)
- PRMIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound ProductsMARIETTA, Ga., Feb. 04, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced it has entered into an exclusive agreement with Summit Products Group ("Summit") to distribute three innovative, 510(k) cleared products that complement the Company's leading Surgical & Wound product portfolio: Hydrelix, NovaForm®, and G4Derm® Plus. About the products: Hydrelix Collagen Matrix is a sterile, Type 1 collagen powder, comprised of soluble modified bovine collagen. The product is formulated from hydrolyzed and modified collagens in powdered form, bypassing the need for further enzymatic degradation by the body. This allows the bioactive components of c
- PRMIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®MARIETTA, Ga., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the 15th anniversary of EPIFIX and AMNIOFIX, the Company's placental allografts used in wound care and surgical recovery settings. "We are thrilled to mark the 15th anniversary of our flagship Wound and Surgical products, EPIFIX and AMNIOFIX, which have been instrumental to our pioneering innovation in the space," stated Randall Spencer, MIMEDX Vice President, Clinical Innovation. "Over the years, MIMEDX has changed the paradigm of wound care treatment and surgical recovery. The Company's products have become the placental allografts of choice across many specialti